Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Millennium Management LLC lowered its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 47.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 586,810 shares of the company's stock after selling 533,153 shares during the quarter. Millennium Management LLC owned 0.69% of Syndax Pharmaceuticals worth $7,758,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Virtus ETF Advisers LLC increased its position in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares during the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 14.4% during the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after buying an additional 1,583 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after buying an additional 1,732 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Syndax Pharmaceuticals by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company's stock valued at $706,000 after purchasing an additional 1,811 shares during the last quarter. Finally, R Squared Ltd bought a new position in Syndax Pharmaceuticals in the fourth quarter valued at about $26,000.

Syndax Pharmaceuticals Stock Performance

SNDX stock traded down $0.05 during trading on Friday, hitting $10.57. 1,808,471 shares of the company traded hands, compared to its average volume of 1,785,806. The firm has a market capitalization of $909.52 million, a PE ratio of -2.91 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $25.07. The company has a 50-day moving average of $11.49 and a 200-day moving average of $13.42.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to analysts' expectations of $15.88 million. During the same quarter last year, the business posted ($0.85) EPS. The company's quarterly revenue was up 1900.0% compared to the same quarter last year. Sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SNDX shares. Guggenheim restated a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen raised Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Scotiabank increased their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research note on Tuesday, May 6th. Citigroup cut their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).